SYNTIS BIO, INC. filed a Form D with the Securities and Exchange Commission on 2025-07-02.
SYNTIS BIO, INC. filed a Form D notice of an exempt securities offering with the SEC on July 2, 2025. The filing reports $24.98M sold. Its industry group is Biotechnology. It names Rahul Dhanda (Executive Officer, Director), Robert Langer (Director), Carlo Giovanni Traverso (Director) (SEC Form D, July 2, 2025).
Is this your company?
Sell to companies like SYNTIS BIO, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-07-02 · the record
Pitching, partnering or investing alongside them? See who really runs and owns SYNTIS BIO, INC.
Free to see. No signup.
More on the people and the money behind SYNTIS BIO, INC., from the filings we hold.
Biotechnology raises by companies based in Massachusetts, filed in July 2025, largest first.
Get an email when SYNTIS BIO, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when SYNTIS BIO, INC. raises, hires or launches. No email unless you switch it on.
Watch SYNTIS BIO, INC. →Get the full cited report on SYNTIS BIO, INC.
What the filing shows about SYNTIS BIO, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on SYNTIS BIO, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives SYNTIS BIO, INC.'s address as 135 Morrissey Blvd, Suite 101A, Boston, MA 02125.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
SYNTIS BIO, INC. is a registered filer with the SEC (CIK 1943061) and has filed since 2023-01-17. 3 filings are on record, the latest on 2025-07-02.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
SYNTIS BIO, INC.'s Form D of 2025-07-02 names Rahul Dhanda, Robert Langer, Carlo Giovanni Traverso and 5 more as its officers, directors or promoters.
Its new offerings report $31.30M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 769 filings in Biotechnology, totalled by week.
Rahul Dhanda is named as Executive Officer and Director on the Form D that SYNTIS BIO, INC. filed with the SEC on 2 July 2025, one of 8 people that filing names.
Robert Langer is named as Director on the Form D that SYNTIS BIO, INC. filed with the SEC on 2 July 2025, one of 8 people that filing names.
Carlo Giovanni Traverso is named as Director on the Form D that SYNTIS BIO, INC. filed with the SEC on 2 July 2025, one of 8 people that filing names.
Teymour Boutros-Ghali is named as Director on the Form D that SYNTIS BIO, INC. filed with the SEC on 2 July 2025, one of 8 people that filing names.
Martin Madaus is named as Director on the Form D that SYNTIS BIO, INC. filed with the SEC on 2 July 2025, one of 8 people that filing names.
Teymour Boutros-Ghali is named as Director on the Form D that SYNTIS BIO, INC. filed with the SEC on 2 July 2025, one of 8 people that filing names.
Chenny Zhang is named as Director on the Form D that SYNTIS BIO, INC. filed with the SEC on 2 July 2025, one of 8 people that filing names.
Michael Nannizzi is named as Director on the Form D that SYNTIS BIO, INC. filed with the SEC on 2 July 2025, one of 8 people that filing names.
8 people named on the filing — 1 holding an executive role and 7 as directors only.
Named as of the 2025-07-02 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about SYNTIS BIO, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on SYNTIS BIO, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on SYNTIS BIO, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist SYNTIS BIO, INC.You get an alert in MentionFox the next time this company shows up.
If you're behind SYNTIS BIO, INC.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for SYNTIS BIO, INC.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Boston
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/syntis-bio-inc-form-d-25000001